drugset / Trial / NCT01104922

Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck

NCT01104922 ↗

Phase 2 Completed 48 enrolled David A. Clump, MD, PhD
NaSingle-groupOpen-labelTreatment

Summary

This trial examines survival and toxicity in previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN) treated with radiosurgery and cetuximab and to evaluate the acute and late toxicities associated with the above therapy.

Timeline

Start
2007-12-26
Primary completion
2014-05-21
Completion
2018-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody 250 mg/m2 Intravenous